Diligence memo · auto-generated · as of July 2, 2026
Caladrius Biosciences, Inc.
Caladrius Biosciences, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Caladrius Biosciences, Inc. operates in Biotechnology, based in BASKING RIDGE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Caladrius Biosciences, Inc. has raised $87M in disclosed capital across 8 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $38M on 2014-05-08.
Most recent recorded round closed around 2021-01-25.
Valuation (modeled)modeled
Provath models Caladrius Biosciences, Inc. at approximately $778M (range $50M–$2.7B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.26× the median modeled value of Series B Biotechnology companies in 2019–2021 (118 peers) — value vs value, same stage and era. Within the normal band (126% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 20 months.
Last raise 5.4 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 12.5× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 89% of Biotechnology peers (4293 compared).
Modeled value ranks above 87% of those peers.
Closest niche peers: Pandion Therapeutics Holdco LLC, Ocular Therapeutix, Inc, Insilico Medicine Cayman TopCo, Purigen Biosystems, Inc., Lucira Health, Inc..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.